Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil food effect study in healthy males
NCT06872866Phase 1Recruiting
- Sponsor
- Aspargo Laboratories
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASP-001 in erectile dysfunction (ED) (2 arms), sponsored by Aspargo Laboratories. Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Curve from Time Zero to Last Measurable Concentration at 24 hours and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
ASP-001
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT06872866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872866.